

DERBYSHIRE JOINT AREA PRESCRIBING COMMITTEE (JAPC)
The Derbyshire JAPC “Traffic Light” Classification

For Traffic Light Classification [click here](#)

The JAPC traffic light classification is in place to assist clinicians in making decisions about the medicines and some medical devices they prescribe. The overarching principles underpinning the decision to include a medicine or some prescribable medical devices in the traffic light classification include:

1. Evidence of clinical effectiveness
2. Evidence of cost effectiveness
3. Patient safety
4. Patient convenience and preference

The Derbyshire JAPC traffic light system is divided into five categories:

- RED** Medicines or medical devices considered suitable for a consultant or specialist, usually within a secondary or tertiary care services, to initiate and continue prescribing
- AMBER** Medicines or medical devices that are initiated in secondary care or other specialist setting but are suitable for GPs to continue on-going prescribing under a shared care protocol, once the patient has been stabilised or dose predictable. (See appendix 1 for circumstances where shared care is not appropriate)
- BROWN** Medicines or medical devices JAPC does not recommend for use except in exceptional circumstances
- BLACK** Medicines or medical devices not routinely* recommended or commissioned
- GREEN** Medicines or medical devices regarded as suitable for primary care prescribing

*Unless agreed through the individual funding request route or for people who are on treatment with a **BLACK** drug/device designation prior to JAPCs decision, in which case they should be able to continue treatment until their next medication review where their NHS clinician might consider it appropriate to switch or stop treatment.

RED

Criteria for Classification

- 1) Requires specialist assessment to enable patient selection, initiation and on-going treating
- 2) Requires long term on-going monitoring of efficacy by a specialist and not suitable for shared care
- 3) Requires long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects, or problematic or high cost investigations to identify toxicity)
- 4) Specifically designated as “hospital only” by product licence or by DH/NICE
- 5) Is new to clinical practice and unfamiliar, necessitating a period of accumulation of experience, firstly (and most rapidly) by consultants/specialists
- 6) Is hospital initiated clinical trial material
- 7) Is unlicensed or prescribed “off-label” and unfamiliar to primary care

AMBER

Criteria for Classification

- 1) Requires specialist assessment (for instance to enable patient selection and initiation of treatment)
- 2) Consideration of the drug/device is indicative of significant progression and a need for specialist input (usually as specified in a clinical guideline)
- 3) Requires short or medium term (e.g. 3-6 months) specialist monitoring of efficacy or until the patient is stable or predictable
- 4) Requires short or medium term specialist monitoring of toxicity
- 5) Is rarely used such that GPs are unlikely to see sufficient patients and acquire a working knowledge of the drug/device, thus requiring continued specialist support
- 6) Is relatively new but there is growing experience and can now begin to move into primary care where experience can be gained with support ('managed entry')
- 7) Requires specific long term monitoring for toxicity needing on-going specialist support

BROWN

Criteria for classification


- 1) Lack of data on effectiveness compared with standard therapy
- 2) Lack of data on safety compared with standard therapy
- 3) Known excess of significant adverse events compared with standard therapy
- 4) Lack of data on cost-effectiveness compared with standard therapy
- 5) Less cost-effective than current standard therapy
- 6) NICE guidance
- 7) Not accepted as cost effective compared to other service development opportunities within the CCGs
- 8) Exceptionality where a small cohort of patients may benefit from prescribing can be identified

'BROWN' Combination products

Derbyshire JAPC does not recommend the routine prescribing of ORAL COMBINATION PRODUCTS that are available as the separate constituents, the following reasons may apply:

- The dose of each individual medicines doses cannot be tailored to the patient's needs, potentially leading to risk of over or under dose
- In the event of an allergic /adverse drug reaction/ inefficacy to the combination product then it would be difficult to ascertain the drug molecule which has caused this reaction
- May not be cost effective

BLACK

These drugs are usually classified by the BNF as 'less suitable for prescribing' , and include anti-malarials. The Department of Health has issued guidance (FHSL(95)7) that medication for malaria prophylaxis may not be reimbursed under the NHS. See full traffic light database for information on specific products.

Anything not listed in the BNF e.g. 'herbal medicines' is classified as BLACK. CCG's will not fund homeopathy.

Criteria for classification

- 1) Lack of data on effectiveness compared with standard therapy
- 2) Lack of data on safety compared with standard therapy
- 3) Known excess of significant adverse events compared with standard therapy
- 4) Lack of data on cost-effectiveness compared with standard therapy
- 5) Less cost-effective than current standard therapy
- 6) NICE guidance (negative technology appraisals)
- 7) Not accepted as cost effective compared to other service development opportunities within the CCGs
- 8) Deemed not affordable and/or low priority for CCGs

Unless agreed through the individual funding request route or for people who are on treatment with a **BLACK** drug/device designation prior to JAPCs decision, in which case they should be able to continue treatment until their next medication review where their NHS clinician might consider it appropriate to switch or stop treatment.

GREEN

Drugs/devices for which GPs (or non-medical prescribers in primary care) are able to take full responsibility for initiating and on-going prescribing

Definitions

Specialist/consultant initiation

Consultant/specialist issues the first prescription usually following a consultation because

- a. The patient requires specialist assessment before starting treatment and/ or
 - b. Specialist short term assessment of the response to the drug/device is necessary
- GPs will be asked to continue prescribing when the patient is stable or predictably stable

Specialist/consultant recommendation

The consultant/specialist requests GPs prescribe initial and on-going prescriptions, but ensures

- a. There is no immediate need for the treatment and is in line with discharge policies and
- b. The patient response to the treatment is predictable and safe

How to make an application to classify a drug/device

A medicine/prescribe-able medical device may be referred to Derbyshire JAPC by:

- Trust Drugs and Therapeutics committee
- Guideline group
- Individual prescriber
- Medicines management team

The Derbyshire JAPC will review all relevant factors and classify the medicine or prescribable medical device in line with JAPC traffic light classification.

Drugs/devices not yet classified

Not classified list contains new drug/device launches and new formulations which Derbyshire JAPC does not consider appropriate for inclusion into the local formulary. These are medicines or prescribable medical devices awaiting national or local evidence submissions.

Medicines or prescribable medical devices not included in the traffic lights

It is not possible to classify all medicines or medical devices listed in the BNF within the Derbyshire JAPC traffic light formulary. If a medicine or medical device is not listed on the traffic light system then advice should be sought from the Medicines Management Team and prescribing of these will be at the discretion of individual NHS Trusts and/or GP.

Appendix 1 - Possible circumstances where shared care is not appropriate- hospitals/specialists would normally retain responsibility for prescribing:

- Medicines requiring ongoing specialist intervention and specialist monitoring
- Patients receive the majority of ongoing care, including monitoring, from the provider and the only benefit of transferring care would be to provider costs
- Medicines, which are unlicensed and/or are being used outside of product license (e.g. licensed medicine used for unlicensed indication or at an unlicensed dose) unless there is a recognised evidence base and/or it is standard treatment
- Individual treatment as part of specified packages of care often under specialised commissioning